title: Altered cell viability and proliferation activity of peripheral lymphocytes in patients with Alzheimer's disease.
abstract: OBJECTIVE
  We evaluated cell viability and proliferation activity of peripheral lymphocytes as potential models of neuronal death in Alzheimer's disease (AD).
  
  
  METHODS
  We analyzed the cell viability and proliferation activity of phytohemagglutinin (PHA)-activated lymphocytes from 68 AD patients and 33 normal controls. The cellular measures were made at baseline (0 hr), 24 hrs, 48 hrs, 72 hrs, and 96 hrs after PHA stimulation.
  
  
  RESULTS
  Cell viability in the AD patients was significantly decreased at 72 hrs and 96 hrs, compared with the normal controls. The declining ramp of the proliferation activity from 48 hrs to 72 hrs after PHA stimulation was significantly related to cell viability at 72 hrs and at 96 hrs in the AD patients.
  
  
  CONCLUSIONS
  Lymphocytes from patients with AD have altered viability and proliferation characteristics in culture following PHA stimulation. These findings suggest that lymphocytes may be used as a peripheral tissue model of cell cycle dysregulation in AD.
authors.affiliation: Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: Se Chang
authors.initials: SC
authors.lastname: Yoon
authors.forename: Young-Ah
authors.initials: YA
authors.lastname: Kwon
authors.forename: Hyeran
authors.initials: H
authors.lastname: Kim
authors.forename: Seonwoo
authors.initials: S
authors.lastname: Kim
authors.forename: Sangmee
authors.initials: S
authors.lastname: Ahn Jo
authors.forename: Doh Kwan
authors.initials: DK
authors.lastname: Kim
references.citation: Rev Neurol. 2001 May 16-31;32(10):901-4
references.pmid: 11424042
references.citation: FASEB J. 1998 Jan;12(1):17-34
references.pmid: 9438407
references.citation: Neurosci Lett. 2002 Jan 11;317(2):81-4
references.pmid: 11755245
references.citation: FASEB J. 2004 Jan;18(1):203-5
references.pmid: 14597556
references.citation: Neuroreport. 2001 Dec 21;12(18):3969-72
references.pmid: 11742221
references.citation: J Clin Invest. 2004 Jul;114(1):121-30
references.pmid: 15232619
references.citation: Neuropsychopharmacology. 2001 Jul;25(1):84-90
references.pmid: 11377921
references.citation: Neurology. 1993 Nov;43(11):2412-4
references.pmid: 8232972
references.citation: Mol Neurobiol. 1995 Feb;10(1):19-45
references.pmid: 7598831
references.citation: J Psychiatr Res. 1975 Nov;12(3):189-98
references.pmid: 1202204
references.citation: JAMA. 2002 May 8;287(18):2335-8
references.pmid: 11988038
references.citation: Prog Neurobiol. 2004 Jan;72(1):1-25
references.pmid: 15019174